Health
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE CLINICAL PHASE 2B/3 STUDY SHOWING COGNITIVE IMPROVEMENT UNDER MASITINIB TREATMENT PHASE 3 CLINICAL STUDY WITH MASITINIB AS A DISEASE-MODIFYING THERAPY FOR ALZHEIMER’S DISEASE HAS BEEN AUTHORIZED BY THE FDA AND KEY EU COUNTRIES Paris, June 23,
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION","length":190,"tagName":"p"},{"type":"text","content":"THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE CLINICAL PHASE 2B/3 STUDY SHOWING COGNITIVE IMPROVEMENT UNDER MASITINIB TREATMENT ","length":133,"tagName":"p"},{"type":"text","content":"PHASE 3 CLINICAL STUDY WITH MASITINIB AS A DISEASE-MODIFYING THERAPY FOR ALZHEIMER’S DISEASE HAS BEEN AUTHORIZED BY THE FDA AND KEY EU COUNTRIES","length":144,"tagName":"p"},{"type":"text","content":"Paris, June 23, 2025, 8am CET","length":29,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced that a new peer-reviewed study from an independent research team based in China (Guangdong Pharmaceutical University and Sun Yat-sen University) presents new evidence showing that masitinib offers a promising new approach to treating Alzheimer’s disease, specifically the most common form, sporadic Alzheimer’s disease (sAD), which accounts for over 95% of all cases.","length":428,"tagName":"p"},{"type":"text","content":"Masitinib is a highly innovative drug for Alzheimer’s disease because unlike the majority of drug development research in this indication, masitinib targets the brain’s innate immune system, including mast cells and microglia. The positioning of masitinib as a treatment of Alzheimer’s disease is also different from other drugs.","length":329,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New evidence from peer-reviewed study","length":37,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":37,"olType":false},{"type":"text","content":"This new pu...